Squarepoint’s Centessa Pharmaceuticals CNTA Stock Holding History

Squarepoint’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,606	Closed	-$2.01M	–	4480
2026 Q1	$2.01M	Sell	50,606 -31,206	-38%	-$798K	﹤0.01%	2181
2025 Q4	$2.05M	Buy	81,812 +62,399	+321%	+$1.58M	﹤0.01%	2046
2025 Q3	$471K	Sell	19,413 -20,347	-51%	-$362K	﹤0.01%	3292
2025 Q2	$522K	Sell	39,760 -3,102	-7%	-$39.3K	﹤0.01%	3242
2025 Q1	$616K	Buy	42,862 +16,056	+60%	+$263K	﹤0.01%	3103
2024 Q4	$449K	Buy	26,806 +6,685	+33%	+$111K	﹤0.01%	3815
2024 Q3	$322K	Buy	+20,121	New	+$246K	﹤0.01%	3396
2021 Q3	–	Sell	-37,771	Closed	-$839K	–	2975
2021 Q2	$839K	Buy	+37,771	New	+$888K	﹤0.01%	1765

Squarepoint's CNTA Position: Q2 2026 in Review

Squarepoint sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 50,606 shares — an estimated $2.01M sold.

Squarepoint first reported a position in CNTA in Q2 2021 and held it in 8 quarters. The position peaked at $2.05M in Q4 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Squarepoint reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 50,606 Centessa Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
Squarepoint first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 8 quarters.
Squarepoint's Centessa Pharmaceuticals position peaked at $2.05M in Q4 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.